Commentary By Sean Cavanaugh, M.D. Associate Editor, Clinical Correlations
With the ever-increasing public concern about drug safety, and the profusion of wave-making research into clinical endpoints, occasional very public collisions are inevitable. And so opens this week’s Shortcuts…
Two recent …
Commentary by Cara Litvin MD, Executive Editor Clinical Correlations
Avandia again made headlines this week when an FDA advisory committee voted to allow the drug to remain on the market despite new data that …
Commentary by Henry Tran, MD
This week we will be highlighting a few articles examining risk factors for the development of obesity & the metabolic syndrome, a treatment for hypertrophic cardiomyopathy, and hospital rankings.
Many people think that soft …
Commentary by Michael Poles MD, Associate Editor Clinical Correlations
Let’s start with a plea to counsel our patients, family members and friends to undergo colorectal cancer screening as it was reported yesterday that President Bush had 5 polyps removed …
Commentary by Judith Brenner MD, Associate Program Director, NYU Internal Medicine Residency Program
This week we focus on breast cancer and the outcome associated with hereditary factors and controversies surrounding the seemingly uncontroversial annual physical exam
This week’s New England Journal of Medicine reports …
This week finds us talking about markers for chronic kidney disease (remember we’re no longer allowed to use terms such as renal insufficiency), a bit of positive news about a popular alternative medicine, a new inflammatory marker for coronary artery disease, a genetic …
Commentary By: Josh Olstein, M.D. Chief Resident Internal Medicine
This week, the NEJM released the results of a survey about needlestick injuries among surgical residents. The frequency of needlestick injuries were quite high, residents averaged 3.8 injuries across all years of training. By …
Commentary By: Sean Cavanaugh MD, Associate Editor Clinical Correlations
Not much in the way of surprise, a lot of the articles in the press this past week focused on cardiovascular health.
In the Lancet, the results of the VALIDD trial (the acronyms are …